Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAA817 versus standard care in PSMA-positive metastatic castration-resistant prostate cancer after Lu-PSMA
MOH_2025-01-22_013866Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Nov 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of actinium-225 PSMA-617 in prostate cancer (PCa) (4 arms), sponsored by Novartis. Started Nov 2024; status: recruiting.
02
Drugs
actinium-225 PSMA-617
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2025-01-22_013866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-01-22_013866.